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Abstract
Background: Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is the most frequent
subtype of secondary HLH triggered by infections. Previous studies have shown that ~30 % or more of patients
with EBV-HLH do not respond to standard therapy. This study investigated the efficacy and safety profile of a
modified DEP regimen in combination with PEG-aspargase (L-DEP) as a salvage therapy for refractory EBV-HLH.
Methods: In this study from October 2014 to October 2015, 28 patients with refractory EBV-HLH received a L-DEP
regimen at the Beijing Friendship Hospital, Capital Medical University. Treatment efficacy and adverse events were
evaluated at 2 and 4 weeks after L-DEP treatment.
Results: Median EBV-DNA concentrations before and 2 weeks after receiving the L-DEP regimen were 9.6 × 105
(1.5 × 104 − 1 × 109) copies/mL and 2.2 × 105 (3.8 × 102 − 1.2 × 107) copies/mL, respectively; the post-treatment
values were significantly lower than that of the pretreatment (P = 0.048). Nine of the 28 study patients achieved
complete response (CR) and 15 partial response (PR), resulting in an overall response rate of 85.7 % (CR+PR). Four
patients who did not achieve response died within 4 weeks of receiving L-DEP. Thirteen of the 24 patients who
achieved partial or complete response received subsequent allogenic hematopoietic stem cell transplantation
(allo-HSCT). Ten of these 13 patients survived until 1 March 2016. The major adverse effects of the L-DEP regimen
were high serum amylase concentrations, abnormal liver function, and coagulation disorders.
Conclusions: This study suggests that L-DEP is a safe and effective salvage therapy prior to allo-HSCT for refractory
EBV-HLH and increases the possibility of such patients receiving allo-HSCT. A prospective multicenter large-scale
clinical trial that aims to validate the L-DEP regimen for refractory EBV-HLH is currently underway (ClinicalTrails.gov
Identifier: NCT02631109).
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Background
Hemophagocytic lymphohistiocytosis (HLH) is a group
of clinical syndromes characterized by fever, hepatosple-
nomegaly, pancytopenia, and hemophagocytic phenom-
ena in the bone marrow, liver, spleen, and lymph tissue.
HLH is divided into two categories: primary and ac-
quired. Primary HLH is an autosomal recessive genetic
disease, whereas acquired HLH is often associated with
and caused by infections, malignant tumors, and auto-
immune diseases. Among the infection-related forms of
HLH, Epstein–Barr virus (EBV) infection-related HLH
(EBV-HLH) is the most common [1], being particularly
common in Asian countries. A previous analysis re-
ported a 1-year overall survival (OS) of only 25.0 % for
patients with EBV-HLH [2]. The main current first-line
treatment for patients with EBV-HLH is the HLH-94
regimen [3], which comprises etoposide, dexamethasone,
and cyclosporine A, with or without intrathecal injection
of methotrexate, followed by allogeneic hematopoietic
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stem cell transplantation (allo-HSCT). Imashuku et al.
[4] reported that the HLH-94 regimen improves the 43-
month survival rate of EBV-HLH patients by 75.6 %.
However, in a previous study of this regimen [3], ap-
proximately 30 % of patients with EBV-HLH had no re-
sponse to therapy, most deaths occurring in the first few
weeks after initiating treatment. In addition, the overall
mortality rate was significantly higher in patients with
active disease at the time of allo-HSCT (P = 0.014) [5].
There is currently no consensus on salvage therapy for
patients with EBV-HLH who fail to respond to HLH-94/
HLH-04 regimens. Identification of effective salvage
therapies that can bridge the gap to allo-HSCT in pa-
tients with refractory EBV-HLH is of utmost importance
and worthy of further research.
In our center, we have used liposomal doxorubicin,
etoposide, and high-dose methylprednisolone (i.e., the
DEP regimen) to treat EBV-HLH patients who have not
achieved response on the HLH-94 regimen and achieved
partial response (PR) or better efficacy in 72.7 % of such
patients [6]. However, the duration of response after this
regimen is relatively short and there is a significant risk
of gastrointestinal bleeding. In this study, we modified
the dosage and duration of methylprednisolone in the
DEP regimen and combined it with PEG-aspargase
(PEG-Asp) regimen (i.e., L-DEP regimen) as salvage
therapy for refractory EBV-HLH and evaluated the effi-
cacy and adverse drug reactions of this combination for
treating EBV-HLH.
Methods
Patients and diagnostic criteria for refractory EBV-HLH
Eligibility criteria for this study were as follows: (1) meet
HLH-04 diagnostic criteria [7], (2) high values for EBV-
DNA copies in the peripheral blood or tissues or num-
ber of cells containing EBV-encoded small RNA (EBER)
in the peripheral blood or tissues, (3) diagnosis of pri-
mary HLH excluded, (4) extranodal lymphoma excluded
by positron emission tomography-computed tomog-
raphy and repeated pathological examination of biopsy
specimens, (5) treated with HLH-94 no less than 2 weeks
before enrollment and did not achieve at least PR, and
(6) did not have acute or chronic pancreatitis or active
gastrointestinal bleeding and had a left ventricular ejec-
tion fraction of ≥50 % at the time of enrollment. In
addition, all patients underwent bone marrow flow cy-
tometry to detect monoclonal cells. The research proto-
col for this study was approved by the Ethics Committee
of Beijing Friendship Hospital, Capital Medical Univer-
sity. All patients provided written informed consent be-
fore participating in the study.
EBV infection was confirmed by identifying signifi-
cantly increased EBV-DNA copies in the peripheral
blood or tissues or number of cells containing EBER in
the peripheral blood or tissues [8]. In the absence of ac-
cepted diagnostic criteria, refractory HLH was defined
according to previous research findings [9] and our clin-
ical experience as failure to achieve at least PR according
to an evaluation 2 weeks after receiving HLH-94 induc-
tion therapy.
L-DEP regimen
The L-DEP regimen used was as follows: PEG-aspargase
2000 U/m2 on day 5; liposomal doxorubicin (doxorubi-
cin hydrochloride liposome injection) 25 mg/m2/day,
day 1; etoposide 100 mg/m2/day on the first day of every
week; and methylprednisolone 15 mg/kg/day for days 1
to 3, 0.75 mg/kg/day for days 4 to 7, and 0.25 mg/kg/day
for days 8 to 10 (Fig. 1). Efficacy was evaluated 2 and
4 weeks after initiating L-DEP salvage therapy. Patients
underwent allo-HSCT as soon as control of their HLH
had been achieved. L-DEP regimen could be repeated
after 3 weeks of salvage therapy in some patients who
had not received further allo-HSCT for various reasons.
Conditioning regimen, donors, and prevention of GVHD
after allo-HSCT
The study patients received total body irradiation (TBI)/
cyclophosphamide/etoposide (VP-16) conditioning (TBI,
4 Gy/day for days −8 to −7; etoposide 5 mg/kg/day for
days −6 to −5; cyclophosphamide, 1.8 g/m2/day for days
−4 to −3) or busulfan/cyclophosphamide/VP-16 condi-
tioning (etoposide 5 mg/kg/day for days −9 to −8; busul-
fan 0.8 mg/kg, every 6 h for days −7 to −5; and
cyclophosphamide, 1.8 g/m2/day for days −4 to −3).
High-resolution HLA typing was performed by poly-
merase chain reaction amplification with sequence-
specific primers to determine HLA-A,-B, -Cw, -DRB1.
and -DQ locus types. All donors underwent EBV-DNA
and natural killer (NK) activity tests and were screened
for the HLH-associated genes to exclude the possibility
of carrying this disease.
All patients received cyclosporine A + methotrex-
ate + anti-thymocyte globulin to prevent graft versus
host disease (GVHD). Cyclosporine A, 3 mg/kg/day,
was intravenously administered from day −8. Metho-
trexate (15 mg/m2/day) was administered on day +1
of the transplant, followed by 10 mg/m2/day on days
+3, +5, and +11. Anti-thymocyte globulin, 3 mg/kg
for patients with HLA-matched-related donors and
8 mg/kg for those with mismatched-related donors,
was also administered.
Evaluation criteria, observed indicators, and
complications
The efficacy of L-DEP for the treatment of EBV-HLH
was assessed according to the evaluation criteria pro-
posed by Marsh et al. [9]. A complete response (CR) was
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defined as normalization of all quantifiable symptoms
and laboratory markers of HLH, including values for sol-
uble CD25, ferritin, triglyceride; hemoglobin; neutrophil
and platelet counts; and alanine aminotransferase (ALT).
A PR was defined as at least a 25 % improvement in two
or more quantifiable symptoms and laboratory markers
by 2 weeks following the L-DEP regimen as follows: sol-
uble CD25 response 1.5-fold decreased; ferritin and tri-
glyceride decreased at least 25 %; an increase by at least
100 % to >0.5 × 109/L in patients with an initial neutro-
phil count of <0.5 × 109/L; an increase by at least 100 %
to >2.0 × 109/L in patients with an initial neutrophil
count of 0.5 to 2.0 × 109/L; and decrease of at least 50 %
in patients with initial ALT >400 U/L. Additionally, the
subjects’ body temperature had to revert to normal
ranges to diagnose either CR or PR. Failure to achieve
PR was defined as no response.
Other observational indicators included EBV-DNA, bili-
rubin, and amylase. Adverse effects and complications, in-
cluding pancreatitis, abnormal liver function, decline in
fibrinogen, infection, hemorrhage and thrombosis, cardiac
dysfunction, and adverse drug reactions were closely mon-
itored during the treatment.
Survival time
Patients received allo-HSCT as soon as control of their
EBV-HLH had been achieved. Survival times were calcu-
lated from the date of L-DEP salvage therapy. All pa-
tients were followed up until death or 1 March 2016,
whichever occurred first.
Statistical analysis
SPSS 16.0 software (SPSS, Chicago, IL, USA) was used
for statistical analysis. Because this was a small study,
data that did not fit a normal distribution are presented
as median and range. Comparisons between multiple
samples and groups were performed using the Wilcoxon
rank sum test. P < 0.05 was considered to denote a sig-
nificant difference, and P < 0.01 was considered very sig-
nificant. Kaplan–Meier survival curves were used to




Twenty-eight patients complied with refractory EBV-
HLH diagnostic criteria and received combined treat-
ment of PEG-aspargase and DEP regimen (L-DEP regi-
men) at the Beijing Friendship Hospital, Capital Medical
University (Beijing, China) from October 2014 to Octo-
ber 2015. The 28 patients with refractory EBV-HLH
comprised including 22 male and six female patients
(male to female ratio = 3.67:1) of a median age of 24 years
(range 7–50 years), 23 of them (82.1 %) being ≥18 years
old. The clinical features at initial presentation and at
the time of diagnosis of refractoriness are presented in
Table 1. According to flow cytometry, 15 patients had
abnormal phenotypes of NK cells in their bone marrow;
however, pathologic examination of bone marrow speci-
mens did not support a diagnosis of lymphoma. These
patients had previously received HLH-94 and one of
them had received combined HLH-94 regimen and
immunization with rituximab monoclonal antibody. The
median time from initial diagnosis of EBV-HLH to initi-
ating the L-DEP regimen was 4 weeks (range, 2–
11 weeks); eight patients (28.6 %) had received the L-
DEP regimen ≤4 weeks from diagnosis. The median time
from the end of HLH-94 to initiating the L-DEP regimen
was 2 weeks (range, 1–8 weeks).
Changes in selected indicators and EBV-DNA before and
after L-DEP regimen
Nine variables were assessed at the time of initial diag-
nosis of EBV-HLH, before, and 2 and 4 weeks after the
L-DEP regimen. These comprised white cell count,
platelet count, alanine aminotransferase, aspartate ami-
notransferase, total bilirubin, lactate dehydrogenase, fi-
brinogen, ferritin, and soluble CD25 (Fig. 2). There were
no significant statistical differences in these variables be-
tween the time of initial diagnosis of EBV-HLH and im-
mediately before L-DEP salvage therapy. White blood
cell counts were significantly higher 4 weeks after the L-
DEP regimen than pretreatment (P = 0.006). Platelet
counts were significantly higher at 2 and 4 weeks after the
L-DEP regimen than pretreatment (P < 0.05), especially
Fig. 1 Protocol for L-DEP regimen
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4 weeks after the L-DEP regimen (P < 0.01). However, ala-
nine aminotransferase, aspartate aminotransferase, and
lactate dehydrogenase concentrations were significantly
lower 2 weeks after the L-DEP regimen (P < 0.05); whereas
total bilirubin values of the patients had not changed
significantly at 2 and 4 weeks after the regimen (P > 0.05).
Fibrinogen, ferritin, and soluble CD25 concentrations
were lower at 2 and 4 weeks after the L-DEP regimen
(P < 0.05).
Of the 28 patients with refractory EBV-HLH, the me-
dian EBV-DNA at the time of initial diagnosis of EBV-
HLH, before and 2 weeks after L-DEP regimen were
1.1 × 106 (1.4 × 103–1 × 109) copies/mL, 9.6 × 105 (1.5 ×
104–1 × 109) copies/mL, and 2.2 × 105 (3.8 × 102–1.2 ×
107) copies/mL, respectively. EBV-DNA values 2 weeks
after L-DEP treatment were significantly lower than pre-
treatment (P = 0.048), whereas EBV-DNA values before
L-DEP and at the time of initial diagnosis of EBV-HLH
did not differ significantly (P = 0.427). EBV-DNA of
three out of 28 patients was reduced to 0 copy/ml at
four weeks after L-DEP regimen, while EBV-DNA of
one patient reduced to 0 copy/ml at eight weeks after
L-DEP regimen.
Responses to L-DEP regimen and allo-HSCT
Nine of the 28 patients with refractory EBV-HLH
achieved CR, 15 achieved PR, and four showed no
evidence of response; thus, the overall response rate
was 85.7 % (CR+PR). Six of the patients with CR and
11 of those with PR received a second cycle of L-
DEP before further treatment because of donor or fi-
nancial problems.
All nine patients with CR underwent allo-HSCT, one
of them from an HLA-identical donor, whereas the
remaining eight underwent haploid allo-HSCT. Of the
15 patients who achieved PR, four underwent haploid
allo-HSCT, four did not undergo allo-HSCT for financial
reasons, and the remaining seven relapsed before receiv-
ing allo-HSCT (4 to 6 weeks after L-DEP). Table 2
shows the clinical features of the 13 patients who re-
ceived allo-HSCT after achieving PR or CR.
Survival time
As of 1 March 2016, 14 of the 28 study patients EBV-
HLH had survived and 14 had died; thus, the mortality
was 50 % and the median survival 18 weeks (range 1–
40 weeks, Fig. 3a). Three of the 13 patients who
achieved PR or CR and underwent subsequent allo-
HSCT died from EBV-HLH recurrence or transplant-
related complications (Table 2). The four patients who
achieved PR but did not undergo allo-HSCT for financial
reasons maintained response for 4 to 20 weeks after L-
DEP and died from relapse. Three of the seven patients
who relapsed before receiving allo-HSCT died, and four
patients are receiving a maintenance regimen at the time
of publication. Four patients who did not achieve re-
sponse died within 4 weeks of the L-DEP regimen.
Patients with EBV-DNA <1 × 105 copies/mL before L-
DEP treatment (n = 5) tended to survive longer than
those with EBV-DNA ≥1 × 105 copies/mL (n = 23);
Table 1 Clinical features of study patients at the time of initial diagnosis and time of identification of refractoriness
Clinical features Initial diagnosis refractoriness
Number (n = 28)/percentage (%) Number (n = 28)/percentage (%)
Fever 28/100.0 28/100.0
Neutrophils <1 × 109/L 15/53.6 13/46.4
Hgb <90 g/L 16/57.1 18/64.3
PLT <100 × 109/L 23/82.1 25/89.3
TG >3 mmol/L 17/60.7 18/64.3
Fgb <1.5 g/L 10/35.7 16/57.1
Ferritin ≥500 μg/L 21/75.0 25/89.3
ALT >40 U/L 24/85.7 24/85.7
TBiL >17.1 μmol/L 16/57.1 18/64.3
LDH >190 U/L 18/64.3 21/75.0
Splenomegaly 28/100.0 28/100.0
Hemophagocytosis 21/75.0 22/78.6
Decline of NK cell activity 17/60.7 18/64.3
Elevated soluble CD25 25/89.3 28/100.0
Positive EBV-DNA in whole blood 28/100.0 28/100.0
Positive EBER in lymph node/bone marrow 3/10.7 4/14.3
Hgb hemoglobin, PLT platelet, Fgb fibrinogen, ALT alanine aminotransferase, TBiL total bilirubin, LDH lactic dehydrogenase
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however, this difference was not statistically significant
(P = 0.247, Fig. 3b). Similarly, patients with EBV-DNA
<1 × 106 copies/mL (n = 12) tended to survive longer
than those with EBV-DNA ≥1 × 106 copies/mL (n = 16);
however, this difference was also not significant (P =
0.083, Fig. 3c). Nevertheless, patients who experienced a
≥1 × 102-fold reduction in EBV-DNA copies after L-DEP
treatment (n = 15) survived significantly longer than
those with <1 × 102-fold reduction in EBV-DNA copies
(n = 13) (P = 0.018, Fig. 3d).
Adverse reactions
Gastrointestinal disorders
Of the 28 patients with EBV-HLH treated with L-DEP,
two developed grade 2 and one patient grade 3 pancrea-
titis. These three patients’ blood amylase concentrations
reverted to normal levels after withholding food and
water, acid-reduction, and somatostatin treatment. One
patient had grade 2 oral mucositis and three patients
grade 1–2 vomiting. One patient had grade 2 gastro-
intestinal bleeding; the remaining patients did not have
grade ≥2 gastrointestinal bleeding.
Abnormal liver function
Of the 28 study patients, three developed increases in
bilirubin concentrations <50 % of the baseline (pretreat-
ment) values and two developed increases in bilirubin
concentrations >50 % of baseline at 2–4 weeks after L-
DEP treatment. Bilirubin concentrations decreased to
below pretreatment values in the remaining patients. No
patients experienced grade ≥3 hepatic failure.
Fig. 2 Changes in white blood cell counts (WBC) (a), platelet counts (b), alanine aminotransferase (ALT) concentrations (c), aspartate
aminotransferase (AST) concentrations (d), total bilirubin (TBiL) concentrations (e), lactate dehydrogenase concentrations (f), fibrinogen (Fbg)
concentrations (g), ferritin concentrations (h), and soluble CD25 concentrations (i) at the time of initial diagnosis of EBV-HLH, before, and 2 and
4 weeks after the L-DEP regimen
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Coagulation disorders
Fibrinogen concentrations were lower than 1.0 g/L in
eight patients before salvage treatment. These patients
received appropriate supportive therapies, including
fresh frozen plasma and fibrinogen. Fibrinogen concen-
trations decreased to below pretreatment values in 20 of
the 28 EBV-HLH patients receiving the L-DEP regimen;
however, no patients developed grade ≥4 diffuse intra-
vascular coagulation.
Infection
Pretreatment bacterial lung infections in 17 patients,
pulmonary fungal infections in 10 patients, and tubercu-
losis infection in two patients did not worsen after ef-
fective anti-infective therapy. Twenty-seven patients
required intravenous antibiotics for grade 3 bronchial in-
fection; however, no patients had ≥grade 4 bronchial in-
fection after therapy.
Bone marrow suppression and cytopenia
Before salvage treatment, neutrophils counts were lower
than 1 × 109/L in 13 patients, hemoglobin concentrations
were lower than 90 g/L in 18 patients, and platelet
counts were lower than 100 × 109/L in 25 patients. Pa-
tients showed declines in neutrophil and platelet counts
and hemoglobin concentrations approximately 1 week
after the L-DEP regimen. However, patients who
achieved response after L-DEP regimen had neutrophil
and platelet counts and hemoglobin concentrations that
were higher than pretreatment values 2 to 3 weeks after
the L-DEP regimen. Two weeks after L-DEP treatment,
neutrophil counts were lower than pretreatment values
in four patients, as were hemoglobin concentrations in
five patients and platelet counts in three patients. How-
ever, these values all decreased by less than 50 % of
baseline values. Marrow toxicity from the L-DEP regi-
men was difficult to evaluate both because cytopenia is a
major clinical feature of EBV-HLH and because counts
are affected by granulocyte colony stimulating factor and
blood transfusion.
Discussion
HLH, an inflammatory cytokine storm caused by uncon-
trolled immune responses, is a rare life-threatening dis-
ease. HLH is divided into two major categories: primary
and acquired. The latter is often caused by infections,
Table 2 Characteristics of patients who underwent allo-HSCT
Patient no. Disease
status




Adverse reactions Outcome Causes of death
1 CR HLA 5/10 related
donor
Sister TBI/Cy/VP-16 CsA + MTX + ATG Recurrence, acute GVHD I,
sepsis
Died Recurrence, sepsis
2 PR HLA5/10 related
donor
Brother TBI/Cy/VP-16 CsA+MTX+ATG Acute GVHD III Survival –
3 CR HLA10/10 related
donor
Sister TBI/Cy/VP-16 CsA+MTX+ATG Pulmonary infection,
acute GVHD II
Survival –
4 CR HLA5/10 related
donor




5 CR HLA5/10 related
donor
Mother TBI/Cy/VP-16 CsA+MTX+ATG Acute GVHD I Survival –
6 PR HLA5/10 related
donor




7 CR HLA5/10 related
donor
Sister Bu/Cy/VP-16 CsA+MTX+ATG Pulmonary infection Survival –
8 CR HLA5/10 related
donor
Brother TBI/Cy/VP-16 CsA+MTX+ATG Acute GVHD I,
gastrointestinal bleeding
Survival –
9 PR HLA5/10 related
donor
Brother TBI/Cy/VP-16 CsA+MTX+ATG Acute GVHD I Survival –
10 CR HLA5/10 related
donor
Father TBI/Cy/VP-16 CsA+MTX+ATG Acute GVHD II, pulmonary
infection
Survival –
11 CR HLA5/10 related
donor
Father TBI/Cy/VP-16 CsA+MTX+ATG Acute GVHD III,
hemorrhagic cystitis
Survival –
12 CR HLA5/10 related
donor
Father TBI/Cy/VP-16 CsA+MTX+ATG – Survival –
13 PR HLA5/10 related
donor
Father TBI/Cy/VP-16 CsA+MTX+ATG Acute GVHD I, pulmonary
infection
Survival –
allo-HSCT allogeneic hematopoietic stem cell transplantation, CR complete response, PR partial response, TBI total body irradiation, Cy cyclophosphamide, VP-16
etoposide, Bu busulfan, CsA cyclosporine A, MTX methotrexate, ATG anti-thymocyte globulin, GVHD graft versus host disease
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malignant tumors, or autoimmune diseases. Infection-
related HLH is mostly attributable to EBV infections,
which account for approximately 70 % of infection-
related cases [1]. EBV-HLH is common in Asian per-
sons; however, it has also aroused attention in non-
Asian countries in recent years. One study [10] has
shown that adults with EBV-HLH have worse prognosis
than children with this disease. However, there are no
published large-scale clinical studies that adequately
examine the prognoses of adults with HLH. In this
study, 82.1 % of participants with EBV-HLH were adults.
Thus, age may have some impact on the interpretation
of the results of this study.
Immune system deficiencies are believed to be in-
volved in the pathogenesis of EBV-HLH. It is well estab-
lished that EBV and its antigens induce massive release
of cytokines, thereby activating monocytes/macrophages
and causing damage in multiple organs [11]. A series of
Japanese-based studies have found that T cells and NK
cells are targeted by EBV infection in patients with EBV-
HLH [12, 13]. Fox et al. [13] reported abundant EBV ge-
nomes (12,900–1,816,550 genomes/106 cells) in the cir-
culating NK cells of such patients. Another study [14]
also showed enhancement of proliferation of latent EBV-
infected lymphocytes and that they contained new sur-
face epitopes. Interestingly, etoposide (VP-16) inhibits
EBV core epitope synthesis and has anti-EBV effects.
One study [15] has shown that early administration of
VP-16 and dexamethasone may reduce the mortality of
EBV-HLH. Imashuku et al. used dexamethasone and
VP-16 as the basic treatment regimen for 78 patients
with EBV-HLH (73 of whom were ≤15 years old) and
achieved a 43-month OS of 75.6 % [4]. Imashuku et al.
[16] also reported enhancement of the long-term sur-
vival of patients with EBV-HLH treated with a regimen
containing etoposide within 4 weeks of diagnosis; how-
ever, they found that treatment of patients with EBV-
HLH with regimens containing cyclosporine made no
significant difference to treatment efficacy or OS. Thus,
the HLH-04 regimen is not significantly better than the
HLH-94 regimen for treating patients with EBV-HLH.
Although we found no significant difference in outcomes
between 4-week HLH-04 and 4-week HLH-94 regimens
in a previous study [2], patients with EBV-HLH who re-
ceived these regimens had significantly better OS than
patients who did not receive etoposide treatment. We
therefore believe that etoposide-based immunochem-
otherapy improve the survival of patients with EBV-
HLH. However, in a study by Henter et al. [3], >30 % of
patients with EBV-HLH did not achieve response with
the HLH-94 treatment regimen. To date, there is no
established second-line treatment for patients with re-
fractory HLH who do not respond to standard treatment
regimens. Allo-HSCT-induced immune reconstitution in
Fig. 3 Survival of patients with refractory EBV-HLH (a). Relationship between the number of pretreatment EBV-DNA copies (1 × 105 copies/mL)
and survival (b). Relationship between the number of pretreatment EBV-DNA copies (1 × 106 copies/mL) and survival (c). Relationship between
declining multiples of EBV-DNA copies and survival after L-DEP regimen (d)
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patients with EBV-HLH can result in them regaining the
ability to remove EBV, thereby prolonging their survival
and ultimately curing HLH. In one Japanese cohort,
allo-HSCT resulted in an 85.7 % 10-year OS for patients
with EBV-HLH [17]. However, allo-HSCT can cause an
increase in transplant-related mortality in patients with
poorly controlled EBV-HLH. In a previous study [2] in
which we performed allo-HSCT in five patients with
EBV-HLH, two of the five patients did not achieve re-
sponse and died within approximately 3 months of diag-
nosis; one patient who did not achieve response after
relapse died 7 months after diagnosis; and the remaining
two patients, who received allo-HSCT while their dis-
ease was stable, survived. Thus, patients with EBV-HLH
who do not achieve response before receiving allo-
HSCT have a significantly reduced OS after transplant-
ation, which is consistent with a previous report [5].
Hence, salvage treatment to stabilize the disease in pa-
tients with refractory EBV-HLH may be important in ex-
tending their survival after allo-HSCT.
Previous studies have demonstrated that anti-
thymocyte globulin [18], tumor necrosis factor-alpha an-
tagonists [19], anti-CD52 monoclonal antibody [9], anti-
CD20 monoclonal antibody [20], and the DEP regimen
[6] can be used as salvage therapy for refractory EBV-
HLH. However, there is no established standard treat-
ment for patients with EBV-HLH who fail to achieve
response with the HLH-94 regimen. Beutel et al. [12]
used rituximab (a CD20 monoclonal antibody) to label
EBV-infected B lymphocytes and successfully treat B
lymphocyte-related HLH. Imashuku et al. [21] postu-
lated that EBV initially infects B cells and then continu-
ously generates viral particles that further infect T or
NK cells, suggesting that rituximab may be an effective
treatment for EBV-infected T or NK cells. Based on the
above theory, researchers have used rituximab to treat
EBV-HLH; however, only retrospective studies and case
reports are available. Chellapandian et al. [20] retro-
spectively analyzed the clinical information of 42 pa-
tients with EBV-HLH who received a rituximab
monoclonal antibody treatment regimen. Rituximab-
containing regimens appeared well tolerated and im-
proved clinical status in 43 % of patients. However, no
large follow-up studies of rituximab therapy in patients
with EBV-HLH have been reported since 2013. In the
study, one patient did not achieve response after a com-
bination of rituximab monoclonal antibody and the
HLH-94 regimen and further received the L-DEP regi-
men to achieve CR, which was followed by allo-HSCT.
In our previous study, we used liposomal doxorubicin,
etoposide, and high-dose methylprednisolone (i.e., the
DEP regimen) to treat patients with EBV-HLH who did
not achieve response after HLH-94; 72.7 % of those pa-
tients achieved PR or better treatment outcomes [6].
However, the duration of the consecutive treatment ef-
fect of the DEP regimen is relatively short and this regi-
men carries a significant risk of gastrointestinal bleeding.
In this study, we modified the dosage and duration of
methylprednisolone in the DEP regimen and combined
it with PEG-aspargase (i.e., the L-DEP regimen) as sal-
vage therapy for refractory EBV-HLH; this combination
increased the overall response rate to 85.7 % and en-
abled more patients to receive allo-HSCT, including all
those who achieved CR (100 %). Thirteen of the 28 pa-
tients with EBV-HLH received allo-HSCT. Only one pa-
tient received allo-HSCT from an HLA-identical donor
and the remaining 12 patients underwent haploid allo-
HSCT, which solved the limitation of donor problem
due to “one-child” policy in China. Ten of these 13 pa-
tients survived (76.9 %) after allo-HSCT. Fifteen of the
28 study patients did not receive allo-HSCT for various
reasons. Despite four (26.7 %) of the 15 patients are con-
tinuously receiving maintenance treatment at the time of
publication, the remaining 11 patients do not survive.
L-DEP is a modified regimen in which PEG-aspargase
is combined with the DEP regimen. PEG-aspargase, a
new asparaginase preparation with a chemical coupling
of modification in polyethylene glycol, not only retains
the biological activity of L-asparaginase but also reduces
its immunogenicity and its half-life from 20 h to 5.5 days,
which may explain the improved treatment efficacy
achieved by combining the DEP regimen with PEG-
aspargase. Ando et al. [22] have reported that L-
asparaginase induces in vitro apoptosis in NK lymphoma
cells. In the present study, 15 of the 28 patients (53.6 %)
demonstrated abnormal phenotypes of NK cells in the
bone marrow as assessed by flow cytometry. In addition,
these patients had significantly fewer EBV-DNA copies
2 weeks after L-DEP regimen than pretreatment (P =
0.048), EBV-DNA being undetectable after L-DEP regi-
men in four patients. We speculate that PEG-aspargase
targets EBV-infected target cells, including T and NK
cells, because these cells may not be able to synthesize
L-asparagine themselves [22]. After entering cells, PEG-
aspargase induces hydrolysis of L-asparagine, thus pre-
venting target cells without L-asparagine (essential
amino acids for protein syntheses) from synthesizing the
corresponding proteins, ultimately inhibiting cellular
proliferation and resulting in decline in EBV-DNA. An
in vitro study by Jinta et al. [23] demonstrated that L-
asparaginase dose-dependently reduces the number of
EBV-positive T and NK cells; while not affecting the per-
ipheral blood mononuclear cells of normal donors, sug-
gesting that L-asparaginase inhibits the proliferation of
EBV-positive T cells and NK tumor cells. A previous
study [24] showed that high viral load of EBV-DNA may
be a risk factor for poor outcomes. The patients less than
1 × 103 copies/mL of EBVDNA showed a significantly
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higher clinical response and longer overall survival than
those with high viral load of EBV-DNA. Another study [2]
has shown that EBV-negativity is an independent risk fac-
tor for prognosis. Patients with EBV-negative conversion
have a significantly better OS than patients who are con-
tinuously EBV-positive. During L-DEP treatment, the clin-
ical status of patients with EBV-HLH improves, usually
accompanied by reduction in EBV-DNA copies or conver-
sion to EBV-DNA negativity. EBV replication is greater in
patients with EBV-HLH with more serious disease man-
ifestations. In this study, prognosis was not significantly
associated with numbers of EBV-DNA copies before the
L-DEP regimen (P > 0.05). However, reduction in EBV-
DNA copies was associated with prognosis. After L-DEP
treatment, reduction of ≥1 × 102-fold in EBV-DNA cop-
ies was significantly associated with prolonged survival
time (P = 0.018).
The DEP regimen is associated with increased risk of
bleeding, especially from the gastrointestinal tract [6].
We therefore modified the DEP regimen by retaining
high-dose corticosteroid therapy to suppress the inflam-
matory cytokine storm and rapidly control the disease.
However, we rapidly decreased the dose of methylpred-
nisolone and stopped it within 10 days, thus reducing
the adverse effects of long-term and high-dose gluco-
corticoid therapy. In this study, no patient developed
≥grade 3 gastrointestinal bleeding. The major adverse ef-
fects of PEG-aspargase are liver dysfunction, decreased
fibrinogen concentrations, and pancreatitis. In this study,
no significant improvements in ALT or lactate dehydro-
genase concentrations were found in the study patients
in the fourth week after L-DEP treatment. In addition,
total bilirubin concentrations 2 and 4 weeks after treat-
ment did not differ significantly from pretreatment
values (P > 0.05). However, other HLH indicators im-
proved compared with pretreatment values, suggesting
that impairment in liver function was caused by PEG-
aspargase, especially in the five patients with higher bili-
rubin concentrations 2 and 4 weeks after treatment than
pretreatment. However, this liver dysfunction was allevi-
ated by liver protection therapy. In this study, fibrinogen
concentrations were significantly lower 2 and 4 weeks
after treatment than pretreatment in the study patients
(P < 0.05), suggesting that this change was associated
with coagulation disorders caused by PEG-aspargase.
Supplementary human fibrinogen and fresh frozen
plasma therapy prevented any serious bleeding in this
cohort. Three patients had increased serum amylase
concentrations after treatment, one of whom developed
abdominal pain and radiographic changes. After somato-
statin therapy, these patients’ amylase concentration
reverted to normal values. In addition, we found that a
low-fat diet after PEG-aspargase treatment appeared to
reduce the incidence of adverse reactions.
Conclusions
In conclusion, our findings suggest that the L-DEP regi-
men is a safe and effective salvage therapy prior to allo-
HSCT for refractory EBV-HLH and enables more pa-
tients to undergo allo-HSCT. Although this was a small
study, we have provided some clinical evidence for the
efficacy of the L-DEP regimen in patients with refractory
EBV-HLH. Our current prospective multicenter and
large-scale clinical trial will further assess the L-DEP
regimen for refractory EBV-HLH (ClinicalTrails.gov
Identifier: NCT02631109).
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